AU2022369026A1 - Novel trimetazidine salts - Google Patents

Novel trimetazidine salts Download PDF

Info

Publication number
AU2022369026A1
AU2022369026A1 AU2022369026A AU2022369026A AU2022369026A1 AU 2022369026 A1 AU2022369026 A1 AU 2022369026A1 AU 2022369026 A AU2022369026 A AU 2022369026A AU 2022369026 A AU2022369026 A AU 2022369026A AU 2022369026 A1 AU2022369026 A1 AU 2022369026A1
Authority
AU
Australia
Prior art keywords
trimetazidine
acid
ppm
salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022369026A
Other languages
English (en)
Inventor
Julien MAHIEUX
Frédéric VILLARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2022369026A1 publication Critical patent/AU2022369026A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022369026A 2021-10-20 2022-10-19 Novel trimetazidine salts Pending AU2022369026A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306465.2 2021-10-20
EP21306465 2021-10-20
PCT/EP2022/079054 WO2023066971A1 (en) 2021-10-20 2022-10-19 Novel trimetazidine salts

Publications (1)

Publication Number Publication Date
AU2022369026A1 true AU2022369026A1 (en) 2024-05-02

Family

ID=78592764

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022369026A Pending AU2022369026A1 (en) 2021-10-20 2022-10-19 Novel trimetazidine salts

Country Status (20)

Country Link
US (1) US20250250245A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419510B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539090A (cg-RX-API-DMAC7.html)
KR (1) KR20240093576A (cg-RX-API-DMAC7.html)
CN (1) CN118076591A (cg-RX-API-DMAC7.html)
AR (1) AR127403A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022369026A1 (cg-RX-API-DMAC7.html)
CR (1) CR20240157A (cg-RX-API-DMAC7.html)
DK (1) DK4419510T3 (cg-RX-API-DMAC7.html)
ES (1) ES3057370T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251413T1 (cg-RX-API-DMAC7.html)
IL (1) IL311916A (cg-RX-API-DMAC7.html)
LT (1) LT4419510T (cg-RX-API-DMAC7.html)
MA (1) MA66951B1 (cg-RX-API-DMAC7.html)
MX (1) MX2024004714A (cg-RX-API-DMAC7.html)
PL (1) PL4419510T3 (cg-RX-API-DMAC7.html)
PT (1) PT4419510T (cg-RX-API-DMAC7.html)
RS (1) RS67449B1 (cg-RX-API-DMAC7.html)
SI (1) SI4419510T1 (cg-RX-API-DMAC7.html)
WO (1) WO2023066971A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106477A1 (en) * 2023-11-14 2025-05-22 Samsara Therapeutics Inc. Novel autophagy inducing compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104138376A (zh) * 2013-05-06 2014-11-12 常州高新技术产业开发区三维工业技术研究所有限公司 一种提高缺氧耐受力的缓释剂
FR3027803B1 (fr) 2014-11-05 2018-02-09 Les Laboratoires Servier Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion
CN105287564A (zh) * 2015-09-06 2016-02-03 余祖江 一种防治肝病的西药复合物及其用途
CN110183398B (zh) 2019-05-14 2021-06-29 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN110105307B (zh) 2019-05-14 2021-06-01 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN110054599B (zh) * 2019-05-14 2021-05-07 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN112043691A (zh) * 2019-06-06 2020-12-08 常州高新技术产业开发区三维工业技术研究所有限公司 一种药物组合物及其用途

Also Published As

Publication number Publication date
IL311916A (en) 2024-06-01
CR20240157A (es) 2024-05-22
EP4419510B1 (en) 2025-10-08
ES3057370T3 (en) 2026-03-02
WO2023066971A1 (en) 2023-04-27
JP2024539090A (ja) 2024-10-28
LT4419510T (lt) 2025-12-29
CN118076591A (zh) 2024-05-24
CA3234743A1 (en) 2023-04-27
US20250250245A1 (en) 2025-08-07
RS67449B1 (sr) 2025-12-31
AR127403A1 (es) 2024-01-17
KR20240093576A (ko) 2024-06-24
EP4419510A1 (en) 2024-08-28
HRP20251413T1 (hr) 2025-12-19
MA66951B1 (fr) 2025-12-31
PT4419510T (pt) 2026-01-02
SI4419510T1 (sl) 2026-01-30
MX2024004714A (es) 2024-05-10
DK4419510T3 (da) 2025-11-17
PL4419510T3 (pl) 2026-02-16

Similar Documents

Publication Publication Date Title
KR102715956B1 (ko) 리보시클립 염 및 이의 고상 형태
EP2791141B1 (en) Tofacitinib mono-tartrate salt
JP2008509953A (ja) 4−[[(7r)−8−シクロペンチル−7−エチル−5,6,7,8−テトラヒドロ−5−メチル−4−6−オキソ−2−ピペリジニル]アミノ]−3−メトキシ−n−(1−メチル−4−ピペリジニル)ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
CN115968370B (zh) Iap拮抗剂化合物和中间体及其合成方法
US20160251314A1 (en) 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
EP4419510A1 (en) Novel trimetazidine salts
US11390637B2 (en) Salts of antiviral phosphonate analogues and process for preparation thereof
CA3234743C (en) Novel trimetazidine salts
WO2011015883A1 (en) Dichloromethane solvate of tiotropium bromide and its use
KR100830002B1 (ko) 시부트라민의 무기산염
HK40115749B (en) Novel trimetazidine salts
HK40115749A (en) Novel trimetazidine salts
EA002164B1 (ru) (1r, 2s, 4r)-(-)-2-[n,n-(диметиламиноэтокси)]-2-фенил-1,7,7-триметилбицикло [2,2,1]гептан высокой степени чистоты, его фармацевтически приемлемые кислотные аддитивные соли, способ получения этих соединений и их применение, а также лекарственные средства, содержащие одно или более из этих соединений
CA3108007C (en) Highly stable crystalline eltrombopag monoethanolamine salt form d1
EA048901B1 (ru) Новые соли триметазидина
KR20260070540A (ko) 환원형 β-니코틴아미드 모노뉴클레오티드 칼슘염의 다형체 및 이의 제조 방법과 용도
WO2015008221A1 (en) Novel crystalline forms of pemetrexed tromethamine salts
EP4698157A2 (en) Novel trimetazidine solid phases
HK40108623A (en) Novel trimetazidine salts
HK40130959A (en) Novel trimetazidine solid phases
KR102623581B1 (ko) 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물
US20240166654A1 (en) Ruxolitinib crystal and pharmaceutical composition thereof
KR20210073972A (ko) (r)-2-((4-아미노페네틸)아미노)-1-페닐에탄올의 신규한 제조방법
KR101761466B1 (ko) 신규한 테노포비어 디소프록실 캠실레이트, 이의 결정형 및 이의 제조방법
WO2017195086A1 (en) Salts of n,n-dimethylbiguanide and preparation methods thereof